Bioventix (LON:BVXP) Share Price Passes Above Fifty Day Moving Average – Time to Sell?

Bioventix PLC (LON:BVXP) passed above its fifty day moving average during trading on Monday . The stock has a fifty day moving average of GBX 1,605.37 and traded as high as GBX 1,823. Bioventix shares last traded at GBX 1,756, with a volume of 3,715 shares changing hands.

Bioventix Stock Performance

The stock has a market capitalization of £93.16 million, a price-to-earnings ratio of 12.69 and a beta of 0.48. The business has a 50-day moving average of GBX 1,605.37 and a 200-day moving average of GBX 1,848.48.

Bioventix (LON:BVXP) last announced its earnings results on Monday, March 30th. The biotechnology company reported GBX 69.38 earnings per share (EPS) for the quarter. The firm had revenue of GBX 615.88 billion during the quarter. Bioventix had a return on equity of 65.83% and a net margin of 59.30%. On average, research analysts predict that Bioventix PLC will post 166.3066955 earnings per share for the current fiscal year.

Insider Transactions at Bioventix

In other news, insider Ian James Nicholson bought 1,000 shares of the firm’s stock in a transaction that occurred on Friday, April 10th. The stock was purchased at an average cost of GBX 1,848 per share, with a total value of £18,480. Also, insider Peter John Harrison bought 1,065 shares of the firm’s stock in a transaction that occurred on Wednesday, April 8th. The stock was purchased at an average cost of GBX 1,849 per share, with a total value of £19,691.85. 6.16% of the stock is owned by corporate insiders.

Bioventix Company Profile

Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. The company offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, oncology, and miscellaneous indications; and Pyrene (HOP-G) ELISA kit to monitor human exposure to industrial pollutants. It also provides contract SMAs and recombinant services. Bioventix PLC was incorporated in 2003 and is based in Farnham, United Kingdom.